TY - JOUR
T1 - miR-625-3p and lncRNA GAS5 in liquid biopsies for predicting the outcome of malignant pleural mesothelioma patients treated with neo-adjuvant chemotherapy and surgery
AU - Kresoja-Rakic, Jelena
AU - Szpechcinski, Adam
AU - Kirschner, Michaela B.
AU - Ronner, Manuel
AU - Minatel, Brenda
AU - Martinez, Victor D.
AU - Lam, Wan L.
AU - Weder, Walter
AU - Stahel, Rolf
AU - Früh, Martin
AU - Cerciello, Ferdinando
AU - Felley-Bosco, Emanuela
N1 - Funding Information:
Funding: This research was funded by the Swiss National Science Foundation grant 320030_182690 and the Stiftung für Angewandte Krebsforchung.
Publisher Copyright:
© 2018 by the authors.
PY - 2019
Y1 - 2019
N2 - Combining neo-adjuvant chemotherapy and surgery is part of multimodality treatment of malignant pleural mesothelioma (MPM), but not all patients benefit from this approach. In this exploratory analysis, we investigated the prognostic value of circulating miR-625-3p and lncRNA GAS5 after neo-adjuvant chemotherapy. 36 MPM patients from the SAKK 17/04 trial (NCT00334594), whose blood was available before and after chemotherapy were investigated. RNA was isolated from plasma and reverse transcribed into cDNA. miR-16-5p and β-actin were used as a reference gene for miR-625-3p and GAS5, respectively. After exclusion of samples due to hemolysis or RNA degradation, paired plasma samples from 32 patients before and after chemotherapy were further analyzed. Quantification of miR-625-3p levels in all 64 samples revealed a bimodal distribution and cloning and sequencing of miR-625-3p qPCR product revealed the presence of miR-625-3p isomiRs. Relative change of the circulating miR-625-3p and GAS5 levels after chemotherapy showed that increased circulating miR-625-3p and decreased GAS5 was significantly associated with disease progression (Fisher's test, p = 0.0393). In addition, decreased levels of circulating GAS5 were significantly associated with shorter overall and progression-free survival. Our exploratory analysis revealed a potential value of circulating non-coding RNA for selection of patients likely to benefit from surgery after platinum-based adjuvant chemotherapy.
AB - Combining neo-adjuvant chemotherapy and surgery is part of multimodality treatment of malignant pleural mesothelioma (MPM), but not all patients benefit from this approach. In this exploratory analysis, we investigated the prognostic value of circulating miR-625-3p and lncRNA GAS5 after neo-adjuvant chemotherapy. 36 MPM patients from the SAKK 17/04 trial (NCT00334594), whose blood was available before and after chemotherapy were investigated. RNA was isolated from plasma and reverse transcribed into cDNA. miR-16-5p and β-actin were used as a reference gene for miR-625-3p and GAS5, respectively. After exclusion of samples due to hemolysis or RNA degradation, paired plasma samples from 32 patients before and after chemotherapy were further analyzed. Quantification of miR-625-3p levels in all 64 samples revealed a bimodal distribution and cloning and sequencing of miR-625-3p qPCR product revealed the presence of miR-625-3p isomiRs. Relative change of the circulating miR-625-3p and GAS5 levels after chemotherapy showed that increased circulating miR-625-3p and decreased GAS5 was significantly associated with disease progression (Fisher's test, p = 0.0393). In addition, decreased levels of circulating GAS5 were significantly associated with shorter overall and progression-free survival. Our exploratory analysis revealed a potential value of circulating non-coding RNA for selection of patients likely to benefit from surgery after platinum-based adjuvant chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85069909994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069909994&partnerID=8YFLogxK
U2 - 10.3390/NCRNA5020041
DO - 10.3390/NCRNA5020041
M3 - Article
AN - SCOPUS:85069909994
SN - 2311-553X
VL - 5
JO - Non-coding RNA
JF - Non-coding RNA
IS - 2
M1 - 41
ER -